Related Experiment Videos
Beta adrenoreceptor subtype cross regulation in the human heart
J A Hall1, A Ferro, J E Dickerson
1Clinical Pharmacology Unit, University of Cambridge.
British Heart Journal
|April 1, 1993
Summary
Selective beta 1 blocker treatment sensitizes cardiac beta 2 adrenoreceptors, potentially reducing their effectiveness in treating heart conditions. This finding questions the optimal beta blocker choice for patients with ischemic heart disease.
Area of Science:
- Cardiology
- Pharmacology
- Adrenergic Receptor Research
Background:
- Beta-1 blockers are commonly prescribed for cardiovascular conditions.
- Understanding the effects of beta-blockers on adrenergic receptor sensitivity is crucial for optimizing treatment.
- Selective beta-1 blockade aims to minimize side effects by targeting specific receptors.
Purpose of the Study:
- To investigate if beta-1 blocker treatment leads to selective beta-2 adrenoreceptor sensitization.
- To determine if this sensitization is confined to the heart.
- To assess the clinical implications for patients with ischemic heart disease.
Main Methods:
- A placebo-controlled, cross-over study involving six healthy volunteers.
- Participants received either a selective beta-1 blocker (bisoprolol) or placebo daily for two weeks.
- Cardiac receptor responsiveness was measured via treadmill exercise and salbutamol injections.
Main Results:
- Bisoprolol treatment enhanced cardiac beta-2 adrenoreceptor responsiveness to salbutamol.
- No significant changes were observed in cardiac beta-1 adrenoreceptor responsiveness or vascular beta-2 receptors.
- Salbutamol-induced hypokalemia was potentiated after bisoprolol treatment.
Conclusions:
- In vivo beta-1 blocker treatment induces cardiac beta-2 adrenoreceptor sensitization.
- This cross-sensitization may impact the efficacy of beta-1 blockers in preventing arrhythmias in ischemic heart disease.
- The findings necessitate a re-evaluation of the most appropriate beta-blocker selection for these patients.